A Phase III Trial Evaluating the Efficacy and Safety of the House Dust Mite (HDM) Sublingual Immunotherapy (SLIT)-Tablet in Children and Adolescents (5-17 Years) With HDM Allergic Asthma
Latest Information Update: 23 Oct 2023
At a glance
- Drugs House dust mite allergy immunotherapy-ALK Abello (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- Acronyms MAPIT
- Sponsors ALK-Abello
- 30 Nov 2022 Status changed from active, no longer recruiting to completed.
- 09 Sep 2022 This trial has been Discontinued in Germany (End Date: 10 Aug 2023), according to European Clinical Trials Database record.
- 10 Aug 2022 This trial has been completed in Bulgaria, according to European Clinical Trials Database record